Final Program

MONDAY • MAY 16 215
B88
BEHAVIORAL • CLINICAL • TRANSLATIONAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 2.0
IMPROVING REAL WORLD CARE THROUGH
INNOVATIVE TRIAL DESIGNS
Assemblies on Behavioral Science and Health Services Research;
Critical Care; Thoracic Oncology
2:15 p.m. - 4:15 p.m. MOSCONE CENTER
Room 306/308 (South Building, Esplanade Level)
Target Audience
Pulmonary and critical care clinicians, trainees, clinical researchers.
Objectives
At the conclusion of this session, the participant will be able to:
• understand and learn about novel techniques in clinical trial design;
• learn new findings about management of respiratory infection, lung cancer, and
pulmonary nodules;
• better apply clinical trial findings to making decisions for individual patients.
Pulmonary, sleep, and critical care medicine are plagued with expensive negative
clinical trials that do not change clinical practice. To advance patient care in an
increasingly resource constrained research environment, innovative, creative study
designs have evolved. These designs move beyond traditional approaches that
largely explore one intervention in one disease in a single population to monitoring
multiple treatments and combinations of treatments in real world populations. In this
symposium, we will use exemplars from recent and ongoing high profile trials across
the fields of pulmonary and critical care medicine to show how novel designs can
greatly improve efficiency, value, and translatability of findings to individual patients.
Chairing: H.C. Prescott, MD, MA, Ann Arbor, MI
V. Liu, MD, MS, Oakland, CA
S.J. Bartlett, PhD, Montreal, Canada
2:15 Novel Trial Designs to Optimize Efficiency and Real World
Impact
S.J. Bartlett, PhD, Montreal, Canada
2:20 PREPAREing for Future Epidemics: Platform Trial with
Adaptive Randomization
A. Nichol, MD, Dublin, Ireland
2:40 Personalizing Care for Lung Cancer: Testing 10 Treatments All
at Once
J. Kern, MD, Denver, CO
3:00 Real World Management of Lung Nodules: Large Pragmatic
Trials
M.K. Gould, MD, MS, Pasadena, CA
3:20 Making Trials More Useful by Analyzing RCTs for
Heterogeneity of Treatment Effects
T.J. Iwashyna, MD, PhD, Ann Arbor, MI
3:35 Evaluative Frameworks to Confirm Research Paradigms Work
as Intended
D. Hickam, MD, MPH, Washington, DC
3:50 Panel Discussion
W.M. Vollmer, PhD, Portland, OR
S.D. Halpern, MD, PhD, Philadelphia, PA
L. Reineck, MD, Bethesda, MD
This session and the International Conference are supported by an educational grant from
AstraZeneca LP.
All CME sessions have been planned and implemented in accordance with the Essential
Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME)
and are free of the control of commercial interests.
B89
BASIC • CLINICAL • TRANSLATIONAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 2.0
HEALTH EFFECTS OF INHALED TOXINS: FROM
THE BENCH TO THE TRENCHES: A GLOBAL
PERSPECTIVE
Assemblies on Environmental, Occupational and Population Health;
Clinical Problems
2:15 p.m. - 4:15 p.m. MOSCONE CENTER
Room 2006/2008 (West Building, Level 2)
Target Audience
Basic scientists and translational researchers interested in mechanisms of
inhalation injury and emerging therapies; clinicians treating patients acutely
exposed to inhalational toxins; clinicians, public health physicians, and
epidemiologists involved in long term care of these patients.
Objectives
At the conclusion of this session, the participant will be able to:
• learn new findings regarding lung injury due to inhalational toxins;
• apply this knowledge to the care of individuals presenting with inhalational
lung injury;
• discuss emerging new potential strategies for the treatment of the acute
and chronic effects of lung injury due to inhalational toxins.
The symposium will provide a venue for basic, scientific, clinical, and
epidemiologic researchers to present an overview of our current understanding
of the underlying biology of inhalational lung injury as well as recent advances in
the medical management of specific inhalational toxins. Within this broad field,
we plan to focus on recent global events, which either have affected or are
putting at risk local populations for injury secondary to tear and chlorine gas.
Following mass-inhalational events, those with underlying lung disease are at
increased risk for short and long-term pulmonary and systemic effects, including
increased susceptibility to infections, increased airway hyperreactivity,
development of restrictive lung diseases as well as cardiac abnormalities. With
this session, we aim to improve knowledge of pulmonary and critical care
specialists caring for victims of acute lung injury secondary to inhalational
toxins, as well as providing care for those with chronic respiratory disease
following inhalational injury. Further, we will provide updates and pave the way
for future collaborative endeavors and studies to assess the effectiveness of
countermeasures. We are very fortunate to have a number of outstanding
speakers including the Scientific Committee Chair for the Turkish Thoracic
Society, with direct involvement of patients exposed to massive amounts of tear
gas in Turkey; the Deputy Medical Director of Medecins Sans Frontieres (MSF);
and a disaster epidemiologist, who performed ground-breaking epidemiological
studies on persons exposed to chlorine during the Graniteville train derailment
MONDAY AFTERNOON
ATS 2016 • San Francisco